Tom Turi

Company: Flagship Biosciences

Job title: Chief Science Officer

Bio:

Thomas Turi, Ph.D. currently serves as the Chief Scientific Officer for Flagship Biosciences developing and implementing Spatial Biology and Digital Pathology solutions to accelerate drug development programs. He previously served as the Chief Scientific Officer for Nexelis where he assisted in the development of multiple approved and authorized COVID vaccine programs in addition to overseeing R&D activities in biomarkers and preclinical sciences.

Dr. Turi served Vice President Companion Diagnostics for LabCorp Drug Development (formerly Covance Central Laboratory Services). He joined LabCorp in 2008 to establish the Biomarker Center of Excellence and was integral to the acquisition of the Seattle based Genomics Laboratory and the formation of the Discovery and Translational Services business unit. He has led LabCorp Drug Development’s expansion in Companion Diagnostics (CDx) and support in excess of fifty CDx programs. Previously, Dr. Turi spent fifteen years at Pfizer, where he held a broad array of scientific leadership positions of increasing responsibility. Most recently he served as the Senior Director of Translational Biomarkers and Mechanistic Biology at Pfizer’s laboratories in Groton, Connecticut.

In addition to his current responsibilities, Dr. Turi participates as a mentor for Atlantic Canada’s Bioscience Business Incubator Emergence program. He has served on the Board of Trustees for The Life Sciences Foundation and as a member of the Global Health Research Roundtable of the Indiana Clinical and Translational Sciences Institute. He has previously served on the Board of Directors for Caprion Proteomics (CellCarta) and led several external partnerships including those with Rules Based Medicine, Celera, Incyte, and Affymetrix. He has also participated on grant and program project review boards for NASA’s Section for Biotechnology and Tissue Engineering.

Seminars:

Enabling Precision Medicine Through Digital Pathology 12:40 pm

Expanding the repertoire of biomarkers for patient stratification Implementing digital pathology as an integral component of clinical trials Validation of digital pathology solutionsRead more

day: Day 2 Track B AM